166 related articles for article (PubMed ID: 36751323)
1. Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases.
Fujimura T; Furudate S; Maekawa T; Kato H; Ito T; Matsushita S; Yoshino K; Hashimoto A; Muto Y; Ohuchi K; Amagai R; Kambayashi Y; Fujisawa Y
Skin Health Dis; 2023 Feb; 3(1):e180. PubMed ID: 36751323
[TBL] [Abstract][Full Text] [Related]
2. Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases.
Fujimura T; Maekawa T; Kato H; Ito T; Matsushita S; Yoshino K; Fujisawa Y; Ishizuki S; Segawa K; Yamamoto J; Hashimoto A; Kambayashi Y; Asano Y
J Dermatol; 2023 Jul; 50(7):912-916. PubMed ID: 36938650
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study.
Fujisawa Y; Yoshino K; Kadono T; Miyagawa T; Nakamura Y; Fujimoto M
Br J Dermatol; 2014 Dec; 171(6):1493-500. PubMed ID: 24814962
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K
J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor.
Fujisawa Y; Yoshino K; Fujimura T; Nakamura Y; Okiyama N; Ishitsuka Y; Watanabe R; Fujimoto M
Front Oncol; 2018; 8():46. PubMed ID: 29552543
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study.
Fujisawa Y; Fujimura T; Matsushita S; Yamamoto Y; Uchi H; Otsuka A; Funakoshi T; Miyagi T; Hata H; Gosho M; Kambayashi Y; Aoki M; Yanagi T; Ohira A; Nakamura Y; Maeda T; Yoshino K
Br J Dermatol; 2020 Nov; 183(5):831-839. PubMed ID: 32198756
[TBL] [Abstract][Full Text] [Related]
7. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
9. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
10. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: A single-institution retrospective study of 21 cases.
Seo T; Kitamura S; Yanagi T; Ujiie H
J Dermatol; 2022 Mar; 49(3):383-386. PubMed ID: 34881462
[TBL] [Abstract][Full Text] [Related]
12. A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Oashi K; Shibata T; Namikawa K; Takahashi A; Yokota K; Nakano E; Teramoto Y; Tsutsumida A; Maeda T; Yamazaki N;
BMC Cancer; 2020 Jul; 20(1):652. PubMed ID: 32660439
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y
Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T; Yoshino K; Nakamura M; Kato H; Ito T; Maekawa T; Fujisawa Y; Matsushita S; Amagai R; Yamazaki E; Takahashi M; Tamabuchi E; Hashimoto A; Kambayashi Y; Yamazaki N; Miyata T; Asano Y
Exp Dermatol; 2024 Jan; 33(1):e14976. PubMed ID: 37946551
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
Chin K; Yamamoto S; Takahashi M; Kadowaki S; Kubota Y; Amanuma Y; Okada M; Kanda M; Kimura Y; Nogi Y; Arimitsu Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):302-308. PubMed ID: 36564602
[TBL] [Abstract][Full Text] [Related]
17. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
18. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
19. Update on taxane development: new analogs and new formulations.
Yared JA; Tkaczuk KH
Drug Des Devel Ther; 2012; 6():371-84. PubMed ID: 23251087
[TBL] [Abstract][Full Text] [Related]
20. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]